Effects of Metformin vs. Glibenclamide on Serum Leptin Concentration in Type 2 Diabetic Patients

Mahmood, Isam Hamo; Tawfiq, Haimn A.

doi:10.33899/rjs.2013.77814

Cited by 2 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Likewise, metformin mitigated hyperuricemia [97], restored leptin sensitivity, and reduced serum leptin concentrations in overweight diabetic patients [98]. Metformin could also increase adiponectin expression and boost its secretion from the subcutaneous adipose tissue [99].…”

Section: Discussionmentioning

confidence: 99%

Vitamin D3 potentiates the nephroprotective effects of vildagliptin–metformin combination in a rat model of metabolic syndrome

Wahba

Abdel-Ghany

Ghareib

et al. 2021

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

The current study was conducted to investigate the nephroprotective effects of vildagliptin-metformin combination in an experimental model of fructose/ salt-induced metabolic syndrome (MetS). A major aim was to evaluate the potential capacity of vitamin D3 to potentiate the pleiotropic nephroprotective effects of vildagliptin-metformin combination. MetS was induced in adult male Wistar rats by adding fructose (10%) to everyday drinking water and salt (3%) to the diet for 6 weeks. Along with the same concentrations of fructose/salt feeding, MetS rats were then treated orally with either vildagliptin (10 mg/kg/day)-metformin (200 mg/kg/day) combination, vitamin D3 (10 μg/kg/day), or the triple therapy for a further 6 weeks. The incidence of MetS was confirmed 6 weeks after fructose/salt consumption, when the rats exhibited significant weight gain, dyslipidemia, hyperuricemia, insulin resistance, hyperinsulinemia, and impaired glucose tolerance. At the end of the 12-week experimental period, MetS rats displayed significantly deteriorated renal function, enhanced intrarenal oxidative stress and inflammation together with exaggerated renal histopathological damages and interstitial fibrosis. The study has corroborated antioxidant, anti-inflammatory, and antifibrotic effects of vildagliptinmetformin combination, vitamin D3, and the triple collaborative therapy, conferring renoprotection in the setting of MetS. Due attention has been paid to the crucial role of dipeptidyl peptidase-4 inhibition and sirtuin-1/5 0 adenosine monophosphate-activated protein kinase activation as novel therapeutic targets to optimize renoprotection. The apparent potentiating effect, evoked upon coadministration of vitamin D3 with vildagliptin-metformin combination, may provide a cornerstone for further clinical investigations.

show abstract

Section: Discussionmentioning

confidence: 99%

Vitamin D3 potentiates the nephroprotective effects of vildagliptin–metformin combination in a rat model of metabolic syndrome

Wahba

Abdel-Ghany

Ghareib

et al. 2021

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…Clinical studies have found that metformin has particular influences at the level of the hypothalamic centers which are responsible for satiety and hunger, leading to a reduction in food intake in both diabetic and non-diabetic patients [13]. According to existing evidence, the weight loss property of this medication may be influenced by increased leptin sensitivity [12].…”

mentioning

confidence: 99%

Metformin Affects Plasma Levels of Soluble Leptin Receptors in Type 2 Diabetes Mellitus and Metabolic Syndrome Patients

Ali

Rasool

2023

amj

View full text Add to dashboard Cite

Background: Obesity and insulin resistance elevate plasma leptin, while it lowers plasma levels of soluble leptin receptors (sOB-R). Objectives: To measure the levels of sOB-R in patients with type 2 diabetes mellitus (T2DM) and metabolic syndrome (MetS) and compare it to healthy controls. The study also aimed to investigate the influence of metformin on the levels of sOB-R in patients with T2DM and MetS. Materials and methods: A cross-sectional study was conducted on 66 participants (33 patients and 33 controls). Patients were divided into two groups; Group I included 17 newly diagnosed T2DM patients, and Group II included 16 patients with MetS. Patients were studied before and 3 months after treatment with 850 mg metformin treatment. Group III included 33 non-obese healthy individuals as a control group. Measurements such as height, weight, waist circumference, hip circumference, blood pressure examination, and biochemical tests including fasting blood sugar, HbA1c, total cholesterol (Ch), triglyceride, high-density lipoprotein (HDL), insulin level, plasma sOB-R levels were performed. Ch/HDL ratio, non-HDL cholesterol, Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), Waist Hip Ratio (WHR), and Body Mass Index (BMI) were calculated.Results: No statistically significant difference was found among the groups regarding sOB-R levels initially, but after metformin treatment, T2DM patients showed a significantly higher level (10.19 ng/ml). There was a significant increase in the levels of sOB-R after metformin treatment, as it increased from 7.82 ng/ml to 10.19 ng/ml in T2DM, and from 6.92 ng/ml to 7.82 ng/ml in MetS patients. Conclusion: Metformin significantly increases the plasma levels of sOB-R in T2DM patients but only slightly increases these levels in MetS patients.

show abstract

Effects of Metformin vs. Glibenclamide on Serum Leptin Concentration in Type 2 Diabetic Patients

Cited by 2 publications

References 20 publications

Vitamin D3 potentiates the nephroprotective effects of vildagliptin–metformin combination in a rat model of metabolic syndrome

Vitamin D3 potentiates the nephroprotective effects of vildagliptin–metformin combination in a rat model of metabolic syndrome

Metformin Affects Plasma Levels of Soluble Leptin Receptors in Type 2 Diabetes Mellitus and Metabolic Syndrome Patients

Contact Info

Product

Resources

About